EPISODE · Oct 31, 2025 · 7 MIN
#050 $SVRA’s Inhaled Hype Hits a Wall
from SueWallSt · host SueWallSt
When $SVRA Savara Inc. filed its long-awaited FDA application, investors cheered—until the FDA refused to even review it. In this episode, we dive into the unfolding securities class action accusing Savara of misleading shareholders about its incomplete drug submission. Biotech investors, pharma followers, and Wall Street skeptics this one's for you. Expect sharp breakdowns, timely analysis, and a dose of biotech drama. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
What this episode covers
When $SVRA Savara Inc. filed its long-awaited FDA application, investors cheered—until the FDA refused to even review it. In this episode, we dive into the unfolding securities class action accusing Savara of misleading shareholders about its incomplete drug submission. Biotech investors, pharma followers, and Wall Street skeptics this one's for you. Expect sharp breakdowns, timely analysis, and a dose of biotech drama. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
NOW PLAYING
#050 $SVRA’s Inhaled Hype Hits a Wall
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.